October 10, 2024- Baxter provided a recent update regarding bringing the North Cove facility back online and helping to ensure ongoing supply to patients are top priorities.
Below is an update on Baxter’s supply continuity:
Allocations: As previously shared, Baxter is advancing multiple paths to help ensure we are appropriately managing inventory and minimizing disruption to patient care as we work to fully restore our North Cove manufacturing operations. This includes implementing allocations, which limit what a customer can order based on historical purchases and medical necessity as well as available and projected inventory. Allocations help limit stockpiling and increase the likelihood of equitable access to available products. Baxter’s goal continues to be to restore customers to 100% allocation levels as soon as possible.
Site Status: As shared in our Oct. 7 update, Baxter continues to scale production across its global locations and is working closely with FDA on temporary importation of products to increase available inventory. Based on 1) the current status of our remediation efforts, 2) our expectations regarding our ability to reallocate capacity from other Baxter facilities, and 3) initiation of temporary importation on certain products, our goal is to restart North Cove production in phases and return to 90% to 100% allocation of certain IV solution product codes by the end of 2024.